S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NYSE:CTLT

Catalent - CTLT Stock Forecast, Price & News

$56.05
-0.59 (-1.04%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$55.06
$57.52
50-Day Range
$42.94
$56.64
52-Week Range
$40.69
$115.33
Volume
3.01 million shs
Average Volume
2.59 million shs
Market Capitalization
$10.09 billion
P/E Ratio
23.95
Dividend Yield
N/A
Price Target
$92.40

Catalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
64.9% Upside
$92.40 Price Target
Short Interest
Healthy
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.49mentions of Catalent in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$72,064 Sold Last Quarter
Proj. Earnings Growth
13.95%
From $2.94 to $3.35 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

56th out of 1,025 stocks

Pharmaceutical Preparations Industry

20th out of 498 stocks

CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory manag

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Analysts Set Catalent, Inc. (NYSE:CTLT) PT at $92.40
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Ricky Hopson Sells 643 Shares of Catalent, Inc. (NYSE:CTLT) Stock
Reasons for the Decline of Catalent (CTLT) Stock
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Will Catalent (CTLT) Stock Bounce Back?
Catalent Announces Changes to its Board of Directors
Catalent (CTLT) Expands Facility Capabilities in Shanghai
Bear Of The Day: Catalent (CTLT)
Why Shares of Catalent Fell 36% This Week
Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
Why Is Catalent (CTLT) Stock Down 24% Today?
Catalent, Inc. Reports First Quarter Fiscal 2023 Results
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
11/01/2021
Today
2/05/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$92.40
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+64.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$503 million
Pretax Margin
10.47%

Debt

Sales & Book Value

Annual Sales
$4.83 billion
Cash Flow
$5.82 per share
Book Value
$26.76 per share

Miscellaneous

Free Float
178,920,000
Market Cap
$10.09 billion
Optionable
Optionable
Beta
1.26

Key Executives

  • Alessandro MaselliAlessandro Maselli
    President, Chief Executive Officer & Director
  • Thomas P. CastellanoThomas P. Castellano
    Chief Financial Officer & Senior Vice President
  • Kay SchmidtKay Schmidt
    Senior Vice President-Technical Operations
  • Lim Chin Wei
    Manager-Global Scientific Affairs
  • Julien Meissonnier
    Chief Scientific Officer & Vice President













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2023?

8 equities research analysts have issued 12 month price targets for Catalent's stock. Their CTLT share price forecasts range from $58.00 to $145.00. On average, they predict the company's share price to reach $92.40 in the next twelve months. This suggests a possible upside of 64.9% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2023?

Catalent's stock was trading at $45.01 on January 1st, 2023. Since then, CTLT shares have increased by 24.5% and is now trading at $56.05.
View the best growth stocks for 2023 here
.

Are investors shorting Catalent?

Catalent saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 5,940,000 shares, an increase of 17.2% from the December 15th total of 5,070,000 shares. Based on an average trading volume of 3,140,000 shares, the short-interest ratio is presently 1.9 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our CTLT earnings forecast
.

How can I listen to Catalent's earnings call?

Catalent will be holding an earnings conference call on Tuesday, February 7th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings data on Monday, November, 1st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.06. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a net margin of 8.83% and a trailing twelve-month return on equity of 12.55%. During the same period in the prior year, the firm earned $0.33 EPS.
Read the conference call transcript
.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2023 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of $3.13-$3.54 for the period, compared to the consensus EPS estimate of $3.76. The company issued revenue guidance of $4.63 billion-$4.88 billion, compared to the consensus revenue estimate of $5.08 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.47%), Tran Capital Management L.P. (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Norris Perne & French LLP MI (0.14%), Comerica Bank (0.13%) and Mountain Pacific Investment Advisers Inc. ID (0.11%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $56.05.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $10.09 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.34 on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 2/6/2023 by MarketBeat.com Staff